Sprague Word

The future and more from Richard Sprague

Posted by sprague on December 22, 2004

BusinessWeek, in The End Of Obesity As We Know It, reports on Sanofi-Aventis’ Acomplia, a drug that tackles the cannabinoid type 1 (CB1) receptor in the brain, making people less interested in over-eating or smoking.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

 
%d bloggers like this: